Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Other Operating Expenses (2023 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Other Operating Expenses for 10 consecutive years, with $55.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Operating Expenses fell 53.19% to $55.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $209.1 million, a 5.79% increase, with the full-year FY2025 number at $209.2 million, up 59.85% from a year prior.
  • Other Operating Expenses was $55.0 million for Q4 2025 at Iovance Biotherapeutics, up from $47.7 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $117.4 million in Q4 2024 to a low of -$128.8 million in Q4 2023.
  • A 3-year average of $28.2 million and a median of $44.7 million in 2024 define the central range for Other Operating Expenses.
  • Peak YoY movement for Other Operating Expenses: surged 858.48% in 2024, then crashed 53.19% in 2025.
  • Iovance Biotherapeutics' Other Operating Expenses stood at -$128.8 million in 2023, then surged by 191.22% to $117.4 million in 2024, then plummeted by 53.19% to $55.0 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Other Operating Expenses are $55.0 million (Q4 2025), $47.7 million (Q3 2025), and $56.7 million (Q2 2025).